HTG Molecular Diagnostics Inc (HTGMQ)

HTG Molecular Diagnostics, Inc. is a healthcare technology company focused on precision medicine and molecular profiling. The company develops instruments, consumables, and software designed to automate sample processing and analyze molecular targets. Its marketed panels include products for transcriptome analysis, precision immuno-oncology, miRNA whole-transcriptome testing, diffuse large B-cell lymphoma cell-of-origin assessment, oncology biomarkers, immune response, and mouse mRNA tumor response applications. HTG sells its instruments and consumables directly in the United States and Europe and also uses distributors in parts of Europe and other international markets. Its customers include biopharmaceutical companies, academic research centers, and molecular testing laboratories. Incorporated in 1997 and based in Tucson, Arizona, the company was previously known as HTG, Inc. and adopted its current name in March 2011. HTG Molecular Diagnostics filed for Chapter 11 bankruptcy in June 2023, and on May 21, 2025, its reorganization case was converted to Chapter 7.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.